Semaglutide represents the superior choice for patients seeking maximum weight loss efficacy and who can tolerate gastrointestinal side effects during the initial months of treatment
Its unflavored profile allows it to mix seamlessly into any beverage, making it an easy and effective part of your bedtime ritual
Our Media Release in response to the TGA Final Decision Breaking News: The TGA Announces the Delegates Final Decision to Reschedule the Use of Psilocybin and MDMA for Medical Purposes Read our media release here - 3 February 2023 The TGAs Interim Decisions against Rescheduling The TGAs Interim Decisions against Rescheduling The TGA Announced its Interim Decisions against Rescheduling on 21 October 2022
Cosmos Study September 9, 2025 Dual-Team Study Team A:Kersten Bartelt, RNJoe Deckert, PhD Team B:Blaine Franklin, PT, DPTEric Barkley Key Findings At 24 months post-cessation, 56% of semaglutide, 52% of liraglutide, and 55% of tirzepatide patients kept the weight off or lost additional weight
Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha
Husein El Hadmed H, Castillo RF